Dhokia V D, Madhavan D, Austin A, Morris Craig G
University Hospitals Leicester NHS Trust, Leicester, UK.
Royal Derby Hospital, Derby, UK.
J Intensive Care Soc. 2019 May;20(2):174-181. doi: 10.1177/1751143718772789. Epub 2018 May 28.
We describe the use of Cytosorb™, a synthetic extracorporeal haemoperfusion adsorption column, in the management of two patients with drug induced cholestasis and a third with alcoholic hepatitis and subsequent acute on chronic liver failure. Cytosorb was used in these patients to remove bilirubin and bile acids by supporting impaired excretory hepatic function, alleviating symptoms with the intention of serving as a bridge to endogenous recovery. The first two cases demonstrate favourable biochemical and symptomatic responses; the third case demonstrated a good biochemical response but subsequently died from the complications of multiple organ failure. These cases suggest Cytosorb™ be evaluated as an adjunct to support liver excretory functions in other arenas, such as acute liver failure or overdose. It remains unclear whether extracorporeal therapies removing liver toxins allow faster or more complete spontaneous recovery of endogenous function.
我们描述了使用Cytosorb™(一种合成的体外血液灌流吸附柱)治疗两名药物性胆汁淤积患者和一名酒精性肝炎继发慢性肝衰竭急性发作患者的情况。在这些患者中使用Cytosorb是为了通过支持受损的肝脏排泄功能来清除胆红素和胆汁酸,缓解症状,以期作为内源性恢复的桥梁。前两例显示出良好的生化和症状反应;第三例显示出良好的生化反应,但随后死于多器官功能衰竭并发症。这些病例表明,Cytosorb™应作为一种辅助手段,在其他领域(如急性肝衰竭或药物过量)支持肝脏排泄功能进行评估。目前尚不清楚清除肝毒素的体外治疗是否能使内源性功能更快或更完全地自发恢复。